menu
    • menu
    [{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Silexion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"SIL-204","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ Silexion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Silexion Therapeutics \/ Silexion Therapeutics"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SIL-204","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Evonik","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"SIL-204","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ Evonik","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Evonik"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Public Offering","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"5-fluorouracil","moa":"||KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Silexion Therapeutics

    Menu

    Silexion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

                            Details : The net proceeds from the offering will advance the Company’s pre-clinical studies of SIL-204, which is being evaluated for KRAS G12D/V-mutated Pancreatic Neoplasms.

                            Product Name : SIL-204

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 15, 2025

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIL-204,Fluorouracil,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Silexion’s SIL-204 Shows Synergy With Pancreatic Cancer Chemotherapy

                            Details : SIL 204 is an anti K-ras G12D/V short-interfering RNA, which is being evaluated for KRAS G12D/V-mutated Pancreatic neoplasms in combination with 5-fluorouracil and irinotecan.

                            Product Name : SIL-204

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : SIL-204,Fluorouracil,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Evonik

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

                            Details : Through the collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation will used for SIL-204, Silexion’s siRNA candidate for KRAS mutated Pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Evonik

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Silexion Therapeutics Reports Breakthroughs from SIL-204 Preclinical Studies

                            Details : SIL-204, a second-generation siRNA candidate, is currently undergoing preclinical trials for the treatment of KRAS-G12D/V-mutated pancreatic cancer.

                            Product Name : SIL-204

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed

                            Silexion Therapeutics

                            Israel arrow
                            SCOPE Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Biomotion Sciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Silexion and Moringa Complete Business Combination

                            Details : The combined company will focus on advancing its pipline, including SIL-204, designed to inhibit KRAS oncogenic process in Pancreatic Cancer by delivering siRNA to eliminate the messengers (mRNA).

                            Product Name : SIL-204

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : SIL-204

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Biomotion Sciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth